Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2002-08-28
2008-05-27
Saunders, David A. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S134100, C424S138100, C424S159100, C424S164100, C424S172100, C530S387300, C530S388220, C530S399000, C530S333000, C530S388800, C530S391700
Reexamination Certificate
active
07378094
ABSTRACT:
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % A1488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.
REFERENCES:
patent: 5487890 (1996-01-01), Taylor et al.
patent: 5879679 (1999-03-01), Taylor et al.
patent: 6291239 (2001-09-01), Prodinger et al.
Lindorfer, M. A., Jinivizian, H. B., Foley, P. L., Kennedy, A. D., Solga, M. D. and Taylor, R. P. (2003). “B Cell Complement Receptor 2 Transfer Reaction.” Journal of Immunology, vol. 170, pp. 3671-3678.
Baiu, D. C., Prechl, J., Tchorbanov, A., Molina, H. D., Erdei, A., Sulica, A., Capel, P. J. A. and Hazenbos, W.L.W. (1999). “Modulation of the Humoral Immune Response by Antibody-Mediated Antigen Targenting to complement Reccptors and Fc Receptors.” Journal of Immunology, vol. 162, pp. 3125-3130.
Prechl, J., Tchorbanov, A., Horvath, A., Baiu, D. C., Hazenbos, W., Rajnavolgyi, E. Kurucz, I., Capel, P. J.A. and Erdei, A. (1999). “Targeting of influenza epitopes to murine CR1/CR2 using single-chain antibodies.” Immunopharmacology, vol. 42, pp. 159-165.
Taylor, R. P., Nardin, A. and Sutherland, W. M. (1997). “Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor.” Cancer Immunol. Immunother, vol. 45, pp. 152-155.
Emlen, Woodruff, “Immune Complexes in Systemic Lupus Erythematosus,” Dubois' Lupus Erythematosus, 4thed., Daniel J. Wallace and Bevra Hannahs Hahn, eds., 1993, Chapter 11, pp. 100-107.
Salmon, J.E., “Abnormalities in Immune Complex Clearance and Fc Receptor Function,” Dubois' Lupus Erythematosus, 4thed., Daniel J. Wallace and Bevra Hannahs Hahn, eds., 1993, Chapter 12, pp. 108-119.
Whipple, E.C. et al., “Analysis of the In Vivo Trafficking of Stoichiometric Doses of an Anti-Complement Receptor 1/2 Monoclonal Antibody Infused Intravenously in Mice,” J. Immunol. 2004, 173: 2297-2306.
Prechl, J. et al., “Targeting of Influenza Epitopes to Murine CR1/CR2 Using Single-Chain Antibodies,” Immunopharmacology 42 (1999), 159-165.
Nolte, M.A., et al., “A Conduit System Distributes Chemokines and Small Blood-Borne Molecules Through the Splenic White Pulp,” J. Exp. Med., vol. 198, No. 3, (2003) pp. 505-512.
Campbell, M.J. et al., “Idiotype Vaccination Against Murine B Cell Lymphoma,” J. Immunol. (1987), vol. 139, No. 8, pp. 2825-2833.
Kanter, G., et al. “Cell-Free Production of scFv Fusion Proteins: An Efficient approach for Personalized Lymphoma Vaccines,” Blood, Apr. 15, 2007, No. 109, No. 8, pp. 3393-3399.
Lindorfer Margaret A.
Sutherland William M.
Taylor Ronald P.
Barnes & Thornburg LLP
Saunders David A.
University of Virginia Patent Foundation
VanderVegt F. Pierre
LandOfFree
Therapeutic uses of complement receptor 2 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of complement receptor 2, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of complement receptor 2 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3982407